PharmaResearch Co Ltd

PharmaResearch Co Ltd maintains a strong capital structure with a debt-to-equity ratio of 0.31, indicating a relatively conservative leverage position. The company's liquidity position is characterized by a current ratio of 6.88, suggesting ample short-term liquidity to cover obligations. However, the firm's net cash position is negative after subtracting total debt, signaling potential liquidity risk. Profitability metrics highlight the company's strong performance, with a return on equity (ROE) of 23.95% and a return on assets (ROA) of 15.82%. These figures exceed the typical thresholds for the pharmaceutical industry, indicating efficient use of equity and assets to generate returns. Geographically, PharmaResearch Co Ltd's revenue is concentrated in South Korea, with no disclosed international segments. This concentration may expose the company to regional economic and regulatory risks, though the firm's focus on high-margin prescription drugs mitigates some of these concerns. The company's growth trajectory is supported by a robust operating cash flow of 183.16 billion KRW and a free cash flow of 136.15 billion KRW. Analysts project continued growth, with a mean price target of 529,727.27 KRW and a median price target of 520,000.00 KRW, reflecting positive sentiment among market participants. Risk factors include the company's reliance on a limited number of therapeutic areas and the potential for regulatory changes affecting drug approvals. The firm's dilution risk is currently low, with no significant dilution sources identified in recent filings. However, the negative net cash position after debt suggests a need for careful capital management. Recent events include strong analyst coverage, with 7 strong-buy and 7 buy recommendations, indicating confidence in the company's future performance. No major recent filings or transcripts have been disclosed that would significantly alter the company's risk profile.